American Association for Cancer Research
00085472can172056-sup-186092_2_supp_4299317_nx0198.docx (87.98 kB)

Supplementary Table 4 from ATR Is a Therapeutic Target in Synovial Sarcoma

Download (87.98 kB)
journal contribution
posted on 2023-03-31, 01:08 authored by Samuel E. Jones, Emmy D.G. Fleuren, Jessica Frankum, Asha Konde, Chris T. Williamson, Dragomir B. Krastev, Helen N. Pemberton, James Campbell, Aditi Gulati, Richard Elliott, Malini Menon, Joanna L. Selfe, Rachel Brough, Stephen J. Pettitt, Wojciech Niedzwiedz, Winette T.A. van der Graaf, Janet Shipley, Alan Ashworth, Christopher J. Lord

This file lists Z-score data of the synovial sarcoma (SS) specific hits from the siRNA screen. SS genetic dependencies were identified by comparing the siRNA Z-scores from the SS tumour cell line screens to siRNA Z-score profiles of >130 other tumour cell lines, and genes are ranked according to median difference between the SS tumour cell lines and other tumour cell lines.


Cancer Research UK Programme Grant

Wellcome Trust Studentship

Rubicon Fellowship



Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18–SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we performed a series of parallel, high-throughput small interfering RNA (siRNA) screens and compared genetic dependencies in SS tumor cells with those in >130 non–SS tumor cell lines. This approach revealed a reliance of SS tumor cells upon the DNA damage response serine/threonine protein kinase ATR. Clinical ATR inhibitors (ATRi) elicited a synthetic lethal effect in SS tumor cells and impaired growth of SS patient-derived xenografts. Oncogenic SS18–SSX family fusion genes are known to alter the composition of the BAF chromatin–remodeling complex, causing ejection and degradation of wild-type SS18 and the tumor suppressor SMARCB1. Expression of oncogenic SS18–SSX fusion proteins caused profound ATRi sensitivity and a reduction in SS18 and SMARCB1 protein levels, but an SSX18–SSX1 Δ71–78 fusion containing a C-terminal deletion did not. ATRi sensitivity in SS was characterized by an increase in biomarkers of replication fork stress (increased γH2AX, decreased replication fork speed, and increased R-loops), an apoptotic response, and a dependence upon cyclin E expression. Combinations of cisplatin or PARP inhibitors enhanced the antitumor cell effect of ATRi, suggesting that either single-agent ATRi or combination therapy involving ATRi might be further assessed as candidate approaches for SS treatment. Cancer Res; 77(24); 7014–26. ©2017 AACR.